Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy (NCT00928330)
This multicenter, Phase Ib study is an open label, dose escalation, three-arm study evaluating the safety, tolerability, pharmacokinetics, and activity of oral (PO) GDC 0941 administered in combination with either intravenous (IV) infusion of ado-trastuzumab emtansine (T-DM1, Kadcyla®; Genentech, Inc.) or IV infusion of trastuzumab (Herceptin®;Genentech, Inc.).
This trial is sponsored by Genentech, Inc. 
- Condition: Metastatic Breast Cancer
- Phase: I
- Enrollment: 57
- Start: July 2009
- Completion: January 2014
- Last verified: July 2015
Last Editorial review: July 29, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.